SCHEMBL7904797

SCHEMBL7904797

CS(=O)(=O)CCN1CCN(CCO)CC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.44
KDM4E B2RXH2 1/20 0.43
CHRM2 P08172 1/20 0.38
CHRM1 P11229 1/20 0.38
KMT2A Q03164 3/20 0.37
LMNA P02545 2/20 0.37
HTT P42858 1/20 0.37
MEN1 O00255 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
PKM P14618 1/20 0.36
HSD11B1 P28845 1/20 0.36
CA12 O43570 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CA9 Q16790 1/20 0.36
POLB P06746 2/20 0.35
GAA P10253 1/20 0.34
THRB P10828 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7351993 0.89
SCHEMBL15255350 0.88 ALDH1A1 (0.41) ALDH1A1KDM4ECHRM2CHRM1KMT2A
SCHEMBL13668902 0.87 SMO (0.34) ALDH1A1KDM4EKMT2AMEN1SMO
SCHEMBL12015831 0.82 PAOX (0.39) LMNACA1CA2CA9SMO
SCHEMBL7910011 0.80 DRD2 (0.45) KMT2AMEN1PKMPOLBSMO
SCHEMBL16190266 0.80 POLB (0.35) ALDH1A1KDM4EKMT2APKMPOLB
SCHEMBL2229127 0.80 ALDH1A1 (0.45) ALDH1A1KDM4ECHRM2CHRM1KMT2A
SCHEMBL9790 0.80 ALDH1A1 (0.45) ALDH1A1KDM4ECHRM2CHRM1KMT2A
SCHEMBL2417 0.80 ALDH1A1 (0.45) ALDH1A1KDM4ECHRM2CHRM1KMT2A
SCHEMBL12015832 0.79 CARM1 (0.41) ALDH1A1CHRM2CHRM1KMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230246229-A1 ORGANIC SULFONATE ELECTROLYTE ADDITIVES FOR ZINC BATTERIES Octet Scientific, Inc. 2023-08-03 US disclosed
US-20170009275-A1 SUBSTRATES AND METHODS USEFUL IN SEQUENCING Life Technologies Corporation 2017-01-12 US disclosed
US-9527824-B2 Pharmaceutical composition for preventing or treating cognitive impairment-related disease comprising morpholine or piperazine based compounds, and donepezil KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2016-12-27 US disclosed
US-9220760-B2 Method of modulating the proliferation of medullary thyroid carcinoma cells THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) 2015-12-29 US disclosed
US-20150299787-A1 IMMOBILIZED BUFFER PARTICLES AND USES THEREOF Life Technologies Corporation 2015-10-22 US disclosed
US-20150005306-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING COGNITIVE IMPAIRMENT-RELATED DISEASE COMPRISING MORPHOLINE OR PIPERAZINE BASED COMPOUNDS, AND DONEPEZIL KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2015-01-01 US disclosed
US-20110318820-A1 Immobilized Buffer Particles and Uses Thereof Life Technologies Corporation (US) 2011-12-29 US disclosed
US-20110183416-A1 Method of modulating the proliferation of medullary thyroid carcinoma cells IPSEN PHARMA S.A.S. (FR) 2011-07-28 US disclosed
US-20100261706-A1 SUBSTITUTED TETRACYCLIC 1H-INDENO [1,2-B]PYRIDINE-2(5H)-ONE ANALOGS THEREOF AND USES THEREOF INOTEK PHARMACEUTICALS CORPORATION (US) 2010-10-14 US disclosed
US-20100261706-A1 SUBSTITUTED TETRACYCLIC 1H-INDENO [1,2-B]PYRIDINE-2(5H)-ONE ANALOGS THEREOF AND USES THEREOF INOTEK PHARMACEUTICALS CORPORATION (US) 2010-10-14 US disclosed
WO-2010077663-A2 SUBSTITUTED TETRACYCLIC 1H-INDENO (1,2-B) PYRIDINE-2 (5H)-ONE ANALOGS THEREOF AND USES THEREOF INOTEK PHARMACEUTICALS CORPORATION (US) 2010-07-08 WO disclosed
US-20070259811-A1 Method of modulating the proliferation of medullary thyroid carcinoma cells IPSEN PHARMA S.A.S. (FR) 2007-11-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110183416-A1 Method of modulating the proliferation of medullary thyroid carcinoma cells TRHR, THRB, TSHR ALDH1A1 4723/4885KDM4E 4208/4885CHRM2 2107/4885
US-20100261706-A1 SUBSTITUTED TETRACYCLIC 1H-INDENO [1,2-B]PYRIDINE-2(5H)-ONE ANALOGS THEREOF AND USES THEREOF TNNI3, TNNT2, ALDH1A2 ALDH1A1 46/4885KDM4E 3177/4885CHRM2 1373/4885
US-20070259811-A1 Method of modulating the proliferation of medullary thyroid carcinoma cells SSTR2, SSTR1, SSTR4 ALDH1A1 4053/4885KDM4E 4003/4885CHRM2 1929/4885
US-20150005306-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING COGNITIVE IMPAIRMENT-RELATED DISEASE COMPRISING MORPHOLINE OR PIPERAZINE BASED COMPOUNDS, AND DONEPEZIL PSEN1, PSEN2, APP ALDH1A1 2833/4885KDM4E 2182/4885CHRM2 39/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.